Eton Pharmaceuticals, Inc. (ETON) Return on equity 2019–2025
Eton Pharmaceuticals, Inc. (ETON) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-17.6%FY2025 · since FY2019: -173.6% → -17.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -17.6% | -1.9 pp |
| FY2024 | -15.7% | -9.6 pp |
| FY2023 | -6.0% | +62.9 pp |
| FY2022 | -69.0% | -57.9 pp |
| FY2021 | -11.1% | +147.6 pp |
| FY2020 | -158.7% | +15.0 pp |
| FY2019 | -173.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ETON financial trends
ETON RevenueETON Net incomeETON Net marginETON Gross profitETON Gross marginETON Operating incomeETON Operating marginETON Operating cash flowETON Free cash flowETON Capital expendituresETON Stock buybacksETON Dividends paidETON Total assetsETON Total liabilitiesETON Shareholders’ equityETON overview →